
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
NFE2L3 (NFE2 like bZIP transcription factor 3) encodes a member of the cap'n'collar basic leucine zipper family of transcription factors. The protein heterodimerizes with small musculoaponeurotic fibrosarcoma factors and binds antioxidant response elements in target genes, thereby regulating transcription. NFE2L3 is targeted to the endoplasmic reticulum and nuclear envelope, linking its transcriptional regulatory activity with membrane-associated cellular localization.
The U-2932 cell line was established in 1996 from the ascites of a 29-year-old female patient with diffuse large B-cell lymphoma (DLBCL), following a history of advanced-stage Hodgkin lymphoma treated with multiple chemotherapy and radiotherapy regimens. The cells belong to the activated B-cell (ABC-like) subtype of DLBCL and have been reported to overexpress BCL2, BCL6, and p53. U-2932 contains two distinct subpopulations with different surface expression patterns of CD19, CD20, and CD38, reflecting intraline heterogeneity. This human lymphoma cell line is used as a model for studying B-cell malignancies, tumor heterogeneity, molecular alterations, and therapeutic responses in diffuse large B-cell lymphoma.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 1
Reference Transcript: NM_004289
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?